Friday, 16 June 2017 693 medication use for RA and osteoporosis, and then evaluated the incidence and risk factors for osteoporotic fracture.
FRI0534 REPEATED OSTEOPOROSIS SCREENING IN RHEUMATOID ARTHRITIS: ARE WE COMPLYING WITH GUIDELINES?
A. [2] [3] [4] . Furthermore, the NOF and AACE recommend repeat screening every two years after diagnosis [3, 4] .
Objectives:
• To identify patients with RA and osteoporosis • To identify if international guidelines are being achieved for reassessment of BMD within two years of treatment commencement in keeping with international guidelines. Methods: A database of patients with a diagnosis of RA and osteoporosis who attend the Rheumatology department of the Midlands Regional Hospital, Tullamore since January 2013 was reviewed. Outpatient summaries, date of diagnosis, radiology investigations (DEXA scanning), pharmacological treatment and follow up investigations and treatment were documented. Results: As of August 2016, 770 patients were identified as having RA. 90% of patients had attended the department since 2013. 117 (16.7%) patients were identified as having osteoporosis. Of these, 52.14% of patients were prescribed bisphosphonate therapy, 31.62% denosumab, 9.4% calcium/vitamin D alone, 0.85% other treatment (teriparatide/strontium) and 5.1% were on no treatment. Only 11.9% of these patients had a repeat DEXA scan within two years of starting or changing treatment. 11.1% of patients had repeat DEXA scans booked. The average length of time since a patient's most recent DEXA is 35 months. Conclusions: Repeat DEXA scanning to assess the response to osteoporosis treatment in people with RA within the timeframe recommended by international guidelines has not been achieved. Patients who fail to respond to osteoporotic treatment are not being identified in a timely manner and therefore are at an increased risk of fractures. The results of this audit will make us more vigilant to identify those patients who are treated for osteoporosis that need repeat DEXA scanning to ensure that treatment is efficacious. Background: Anoressia nervosa (AN) is associated with an increased risk of low bone mineral density (BMD) and fractures as a consequence of an inadequate bone mass peak in adolescence and bone loss in young adulthood. Moreover, recently we have showed that vitamin D (25-OH-D) deficiency is widespread in untreated patients with AN, and there is a strong positive relationship between vitamin D status and BMD in AN. However, if vitamin D status could affect the efficacy of weight restoration in improving bone health in patients with AN is currently unknown. Objectives: Our aim was to investigate the potential role of vitamin D status in determining the efficacy on bone mineral density (BMD) of weight restoration in AN. Methods: Bone mineral density assessed by dual-energy x-ray absorptiometry (DXA), vitamin D, N-propeptide of type I collagen (P1NP), C-terminal telopeptide of type I collagen (CTX), intact parathyroid hormone (PTH) were evaluated before and after a 20-weeks intensive weight restoration therapy in patients with anorexia nervosa and secondary amenorrhoea for at least 6-months. The subjects were not receiving medications known to affect bone metabolism. Results: Ninety-one female patients aged 13-45 years old were evaluated, baseline weight 39.4±5.6 kg and BMI 15.1±1.6 kg/m 2 . Weight and BMI were significantly increased in all patients after treatment. The mean BMD values were significantly increased only at the spine (1.0±3.6%, p=0.009). A positive trend was demonstrated between post-treatment 25-OH-D and BMD changes at the spine (p=0.032). However, only the patients with post-treatment 25-OH-D ≥30 ng/ml showed significantly higher increases in BMD at the spine (2.5% vs 0.5% respectively for 25-OH-D ≥30 ng/ml and 25-OH-D <30 ng/ml, p<0.03; Figure  1 ). Both P1NP and PTH increased, whereas a significant decrease was found in 25-OH-D and CTX (p<0.05). Post-treatment CTX levels were inversely correlated with spine BMD. A positive relationship was found between changes in weight and P1NP (R2 =0.27).
Conclusions:
In anorexia nervosa, a hypovitaminosis D status counteracts the efficacy of the weight restoration treatment because of an increase in bone resorption mediated by a secondary hyperparathyroidism. Our study strongly support the use of vitamin D supplements for bone health in anorexia nervosa. 
